Discovery and Development of Novel Biguanides for Metabolic Disease and Cancer
NT1195 is our lead compound for the treatment of Endometrial Cancer and Type 2 Diabetes.
Development of NT1195 for Endometrial Cancer and Type 2 Diabetes
NovaTarg’s drug discovery program, based on activity at organic cation transporters, is targeted at the intersection of metabolic diseases and cancer. Novel biguanides that selectively target endometrial and metabolic tissues will be developed for both type 2 diabetes (T2D) and endometrial cancer (EC).
NT1195 is more potent and efficacious than metformin in animal models of EC and T2D, and has superior drug properties, particularly PK and safety.
NT1195 is a novel biguanide that can properly test the hypothesis, that an optimized biguanide can be an effective treatment for cancers associated with insulin resistance, as well as in the treatment of T2D itself.
IND-enabling studies for the treatment of both EC and T2D are in progress. A pre-IND briefing document has been submitted to FDA and responses from FDA have been incorporated in the plan outlined below.
Development Plan for NT1195